A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
The non-mevalonate (methylerythritol phosphate, MEP) pathway for isoprenoid biosynthesis is essential in Plasmodium spp., but is absent in the human host. The pathway is a clinically validated antimalarial target on basis of studies with the antibiotic fosmidomycin, an inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr, IspC), which catalyses the first committed step of the MEP-pathway. In this review, we report on reverse, hydroxamate-based fosmidomycin analogues, which aredoi:10.1016/j.proche.2015.03.016 fatcat:no4bibwp6ndxnioqb4hqbtzvsy